Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company specializing in acquiring, developing, and commercializing novel treatments for solid tumor cancers. The company's lead products include Cosibelimab, a monoclonal antibody that blocks PD-L1 interaction, CK-302, a human agonistic antibody designed to trigger signaling in GITR expressing cells, Olafertinib for EGFR mutation-positive non-small cell lung cancer, CK-103, a small molecule inhibitor, and an anti-CAIX antibody for recognizing and killing CAIX expressing cells. Checkpoint Therapeutics generates revenue through the development and commercialization of these innovative treatments for cancer patients.

Products

• Cosibelimab

• CK-302

• Olafertinib

• CK-103

• Anti-CAIX antibody